Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in Capricor Therapeutics Inc (NASDAQ:CAPR) by 12.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 79,782 shares of the biotechnology company’s stock after acquiring an additional 9,040 shares during the quarter. Bank of New York Mellon Corp’s holdings in Capricor Therapeutics were worth $381,000 as of its most recent SEC filing.

Separately, Vanguard Group Inc. boosted its holdings in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after acquiring an additional 200,499 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.60.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.00% of the company’s stock.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $10.34 on Thursday. The company has a market capitalization of $336.46 million, a price-to-earnings ratio of -11.88 and a beta of 3.92. Capricor Therapeutics Inc has a 12 month low of $2.68 and a 12 month high of $12.87. The company’s fifty day moving average price is $4.59 and its two-hundred day moving average price is $5.25.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, analysts anticipate that Capricor Therapeutics Inc will post -1.14 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.